Association of Complement C3 Gene Variants with Renal Transplant Outcome of Deceased Cardiac Dead Donor Kidneys by Damman, J. et al.
  
 University of Groningen
Association of Complement C3 Gene Variants with Renal Transplant Outcome of Deceased
Cardiac Dead Donor Kidneys
Damman, J.; Daha, M. R.; Leuvenink, H. G.; van Goor, H.; Hillebrands, J. L.; van Dijk, M. C.;
Hepkema, B. G.; Snieder, H.; van den Born, J.; de Borst, M. H.
Published in:
American Journal of Transplantation
DOI:
10.1111/j.1600-6143.2011.03880.x
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2012
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Damman, J., Daha, M. R., Leuvenink, H. G., van Goor, H., Hillebrands, J. L., van Dijk, M. C., ... Seelen, M.
A. (2012). Association of Complement C3 Gene Variants with Renal Transplant Outcome of Deceased
Cardiac Dead Donor Kidneys. American Journal of Transplantation, 12(3), 660-668.
https://doi.org/10.1111/j.1600-6143.2011.03880.x
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
American Journal of Transplantation 2012; 12: 660–668
Wiley Periodicals Inc.
C© Copyright 2011 The American Society of Transplantation
and the American Society of Transplant Surgeons
doi: 10.1111/j.1600-6143.2011.03880.x
Association of Complement C3 Gene Variants With
Renal Transplant Outcome of Deceased Cardiac Dead
Donor Kidneys
J. Dammana,*, M. R. Dahab,c, H. G. Leuveninka,
H. van Goord, J. L. Hillebrandsd,
M. C. van Dijkd, B. G. Hepkemae, H. Sniederf,
J. van den Bornc, M. H. de Borstc, S. J. Bakkerc,
G. J. Navisc, R. J. Ploega and M. A. Seelenc
aDepartment of Surgery, University Medical Center
Groningen, Groningen, the Netherlands
bDepartment of Nephrology, Leiden University Medical
Center, Leiden, the Netherlands
cDepartment of Nephrology,
dDepartment of Pathology and Medical Biology,
eDepartment of Transplant Immunology,
fDepartment of Epidemiology, Unit of Genetic
Epidemiology & Bioinformatics, University Medical
Center Groningen, Groningen, the Netherlands
*Corresponding author: Jeffrey Damman,
j.damman@umcg.nl
Local renal complement activation by the donor kid-
ney plays an important role in the pathogenesis of
renal injury inherent to kidney transplantation. Con-
tradictory results were reported about the protective
effects of the donor C3F allotype on renal allograft out-
come. We investigated the influence of the donor C3F
allotype on renal transplant outcome, taking all dif-
ferent donor types into account. C3 allotypes of 1265
donor–recipient pairs were determined and divided
into four genotypic groups according to the C3F allo-
type of the donor and the recipient. The four genotypic
groups were analyzed for association with primary
nonfunction (PNF), delayed graft function, acute re-
jection, death-censored graft survival and patient sur-
vival. Considering all donor types, multivariable analy-
sis found no association of the donor C3F allotypewith
renal allograft outcome. Also, for living and deceased
brain-dead donors, no association with allograft out-
come was found. Post hoc subgroup analysis within
deceased cardiac dead (DCD) donors revealed an inde-
pendent protective association of donor C3F allotype
with PNF. This study shows that the donor C3F allo-
type is not associated with renal allograft outcome af-
ter kidney transplantation. Subgroup analysis within
DCD donors revealed an independent protective asso-
ciation of the donor C3F allotype with PNF, which is
preliminary and warrants further validation.
Key words: Cardiac death donors, complement, com-
plement component C3, deceased donor kidneys, de-
ceased donor organs, primary graft dysfunction, renal
transplantation
Abbreviations: ATG, antithymocyte globulin; DBD, de-
ceased brain death; DCD, deceased cardiac death; DGF,
delayed graft function; HLA, human leukocyte antigen;
IRI, ischemia-reperfusion injury; Moab, monoclonal an-
tibody; PNF, primary nonfunction; PRA, panel reactive
antibody; RA, receptor antagonist.
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Introduction
Long-term renal allograft survival after kidney transplan-
tation is affected by different variables including donor
type and age, kidney preservation methods, ischemia-
reperfusion injury (IRI) and acute rejection (1–4). Today,
the majority of renal allografts are recovered from de-
ceased brain-dead (DBD) donors whereas donation after
cardiac death (DCD) has emerged as an important alter-
native donor source to enlarge the deceased donor pool.
Organs recovered from DBD as well as DCD donors have
shown to give inferior transplant outcomes compared to or-
gans recovered from living (un)related donors (5). In DBD
donors, local and systemic immune activation occurs and
is, at least in part, responsible for the pathogenesis of renal
injury of kidney grafts to be. Importantly, a significant part
of the brain death induced immune activation can be as-
cribed to local and systemic complement activation which
is associatedwith reduced renal allograft function (6,7). No-
tably, significant systemic complement activation has been
demonstrated in DCD donors already before withdrawal of
treatment (8).
In renal transplantation, it was demonstrated that comple-
ment activation plays a substantial role in renal IRI and
allograft rejection. Previous studies have shown that com-
plement can also be activated by donor brain death, renal
IRI and allograft rejection (6–9). C3 is the central comple-
ment component that can be activated by all the three
complement pathways (10,11). In mice, it was shown that
absence of local renal C3 in the donor kidney significantly
improves early postreperfusion injury and late rejection as-
sociated allograft survival (12,13). The main producers of
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Figure 1: Kidney transplantations that were included and excluded from the study.
C3 in the kidney are tubular epithelial cells and the re-
jecting transplanted kidney can contribute up to 16% of
all circulating C3 compared to 5% in resting kidneys (14).
Complement C3 can be activated locally in the kidney at
the tubular brush border of proximal tubular epithelial cells,
inducing a proinflammatory response, thereby contributing
to the pathogenesis of tubulointerstitial injury (15–18).
There are two allelic variants of the C3 allotype, namely,
the slow variant (C3S) and the fast variant (C3F) which
is based on the ability of C3 to migrate through a gel-
electrophoresis system (19,20). The C3F allotype is char-
acterized by a functional single nucleotide polymorphism
(C–G) leading to a substitution of glycine (C3F) for arginine
(C3S) at position 80. This might affect the ability of C3
to interact with monocyte complement receptors (21,22).
The frequency of the C3F allotype is highest amongst Cau-
casians (20%) and less frequent in blacks (5%) and Asians
(1%). In human kidney transplantation, conflicting results
about the protective effects of the donor C3F allotype on
allograft outcome of deceased donor kidneys have been
reported (23,24). The disparity could be explained by an
unequal distribution of DBD and DCD donor types among
both studies.
The aim of this study was to investigate the influence of
the donor C3F allotype on renal allograft outcome, taking
all different donor types into account.
Methods
Patients and study design
Between March 7, 1993 and February 12, 2008, 1430 patients underwent
kidney transplantation at the University Medical Center Groningen, the
Netherlands. From this original group, 90 patients were excluded because
of three or more kidney transplantations, simultaneous transplantation of
other organs (pancreas, liver, lung and intestine) and technical problems
during the operation. A total of 4 patients were lost to follow-up, of 65
transplantations, no donor and recipient DNA pairs were available and of 6
patients, no genotype could be assessed (Figure 1). Informed consent was
given by all patients. Donor, recipient and transplant characteristics were
obtained and documented. First, the whole study group (all donor types,
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Table 1: Donor, recipient and transplant characteristics of the whole study group (all donor types, n = 1265) according to the C3 allotype
of the donor and recipient
SS donor SS FS/FF donor SS SS donor FS/FF FS/FF donor FS/FF
Variable recipient (n = 529) recipient (n = 255) recipient (n = 247) recipient (n = 234) p-Value1
Donor characteristics
Age (years)2 47 (34–55) 46 (33–55) 47 (35–56) 47 (38–55) 0.792
Sex no. (%)
Male 269 (51) 139 (54) 114 (46) 120 (51) 0.313
Female 260(49) 116 (46) 133 (54) 114 (49)
Donortype no. (%):
Living 111 (21) 49 (19) 52 (21) 68 (29) 0.037
DBD 335 (63) 161 (63) 164 (66) 124 (53)
DCD 83 (16) 45 (18) 31 (13) 42 (18)
Recipient characteristics
Age (years)2 51 (39–60) 48 (37–59) 48 (38–58) 48 (39–57) 0.061
Sex no. (%)
Male 309 (58) 161 (63) 137 (56) 129 (55) 0.238
Female 220 (42) 94 (37) 110 (44) 105 (45)
PRA level >5% (%) 14 14 20 14 0.461
Previous transplants no. (%)
First transplant 483 (91) 225 (88) 222 (90) 208 (89) 0.538
Second transplant 46 (9) 30 (12) 25 (10) 26 (11)
Primary kidney disease no. (%):
Glomerulonephritis 92 (17) 45 (18) 44 (18) 41 (18) 0.052
Adult polycystic disease 68 (13) 36 (14) 35 (14) 28 (12)
Renal vascular disease 69 (13) 24 (9) 19 (8) 11 (5)
IgA nephropathy 35 (7) 15 (6) 19 (8) 29 (12)
Pyelonephritis 47 (9) 33 (13) 31 (13) 35 (15)
Diabetes 27 (5) 9 (4) 8 (3) 7 (3)
Chronic 71 (13) 35 (14) 30 (12) 31 (13)
Other 120 (23) 58 (23) 61 (25) 52 (22)
Initial immunosuppression no. (%):
Corticosteroids 496 (94) 240 (94) 238 (96) 221 (94) 0.716
Mycophenolic acid 368 (70) 189 (74) 179 (73) 166 (71) 0.703
Cyclosporin 454 (86) 218 (86) 215 (87) 193 (83) 0.238
Azathioprine 28 (5) 12 (5) 14 (6) 18 (8) 0.204
Tacrolimus 38 (7) 18 (7) 20 (8) 20 (9) 0.507
ATG 36 (7) 22 (9) 24 (10) 20 (9) 0.397
Anti-CD3 moab 8 (2) 4 (2) 1 (0) 6 (3) 0.324
Interleukin-2 RA 87 (16) 35 (14) 40 (16) 37 (16) 0.834
Sirolimus 14 (3) 6 (2) 8 (3) 9 (4) 0.366
Transplant characteristics
Cold ischemia time (h)2 18 (12–23) 17 (13–23) 18 (10–23) 17 (3–23) 0.431
HLA no. of 0 mismatches (%) 101 (23) 47 (22) 50 (24) 42 (23) 0.991
DBD = deceased brain death; DCD = deceased cardiac death; PRA = panel reactive antibody; ATG = antithymocyte globulin; moab =
monoclonal antibody; RA = receptor antagonist.
1All p-values are two-sided. Kruskal–Wallis test for continuous variables, and chi-square test for categorical variables.
2Median (interquartile range).
n = 1265) was divided into four genotypic groups according to the pres-
ence or absence of the C3F allotype of the donor or the recipient. As the
frequency of the C3FF allotype in the general population is low, C3FF and
C3FS allotypes were combined and compared with the C3SS allotype in
both the donor and recipient. Following this strategy, four groups were de-
fined: (1) SS donor into SS recipient, (2) FS/FF donor into SS recipient, (3) SS
donor into FS/FF recipient and (4) FS/FF donor into FS/FF recipient (Figure 1,
Tables 1 and 2). Subsequently, the same subdivisionwasmade as described
above but now within living, DBD and DCD donor types separately.
DNA isolation and genotyping
DNA was extracted from peripheral blood samples or splenocytes from
deceased donors using a commercial kit following the manufacturer’s in-
structions. Genotyping of the selected C3 single nucleotide polymorphism
(rs2230199) was performed using the Illumina VeraCode GoldenGate Assay
kit (Illumina, San Diego, CA, USA), according to the manufacturer’s instruc-
tions. Genotype clustering and calling were performed using BeadStudio
Software (Illumina). The overall genotype success rate was 99.5% and six
samples with a high missing call rate were excluded from subsequent
analyses.
Study end-points
The primary end-points in this study were: primary nonfunction (PNF, de-
fined as nonfunctioning of the allograft from transplantation on), delayed
graft function (DGF, defined as the requirement for dialysis within the first
week after transplantation), biopsy proven acute rejection (all biopsies were
662 American Journal of Transplantation 2012; 12: 660–668
Donor C3 Allotype and Renal Allograft Outcome
Table 2: Multivariable analyses for transplant outcome of the whole study group (all donor types, n = 1265) according to the C3 allotype
of the donor and recipient
SS donor SS recipient FS/FF donor SS SS donor FS/FF FS/FF donor FS/FF
Variable (n = 529, reference group) recipient (n = 255) recipient (n = 247) recipient (n = 234) p-Value
Posttransplant follow up (years)1 6.89 7.01 7.09 7.08 0.7892
(6.68 – 7.12) (6.71 – 7.30) (6.80 – 7.38) (6.78 – 7.38)
Death censored graft survival3 1.00(1) 0.78 0.87 0.85 0.793
1.00(2) (0.52–1.18)(1) (0.58–1.30)(1) (0.56–1.31)(1)
0.78 0.85 0.87 0.657
(0.51–1.19)(2) (0.56–1.30)(2) (0.56–1.35)(2)
Patient survival3 1.00(1) 0.93 1.03 0.72 0.518
1.00(2) (0.61 –1.42)(1) (0.68–1.55)(1) (0.45–1.15)(1)
0.99 1.11 0.71 0.501
(0.63–1.56)(2) (0.72 –1.72)(2) (0.42–1.21)(2)
Primary nonfunction3 1.00(1) 0.59 0.82 0.57 0.369
1.00(2) (0.28–1.25)(1) (0.42–1.63)(1) (0.26–1.26)(1)
0.52 0.78 0.54 0.351
(0.23–1.19)(2) (0.36–1.67)(2) (0.22–1.38)(2)
Delayed graft function3 1.00(1) 1.00 0.81 0.90 0.597
1.00(2) (0.73–1.38)(1) (0.59–1.13)(1) (0.65–1.25)(1)
1.08 0.83 1.04 0.627
(0.76–1.55)(2) (0.57–1.21)(2) (0.70–1.53)(2)
Biopsy proven acute rejection 1.00(1) 1.27 1.18 1.03 0.447
(1st year)3 1.00(2) (0.92–1.75)(1) (0.85–1.63)(1) (0.74–1.44)(1)
1.09 1.03 1.06 0.967
(0.75–1.58)(2) (0.71–1.51)(2) (0.71–1.58)(2)
Acute rejection classification no. (%)
Overall 155 (29) 88 (35) 81 (33) 70 (30) 0.4464
Borderline 49 (9) 26 (10) 27(11) 20 (9) 0.8084
Banff IA or IB 64 (12) 39 (15) 34(14) 31 (13) 0.6624
Banff IIA, IIB, III 42 (8) 23 (9) 20 (8) 19 (8) 0.9644
DCD = deceased cardiac death.
1Mean estimate (95% confidence interval).
2Log-rank test.
3Hazard ratios (95% confidence interval).(1)Crude and (2)adjusted for donor and recipient gender and age, donor type, cold ischemia time,
HLA-A, -B and -DR mismatch, transplant number, recipient primary renal disease.
4Chi-square test.
re-evaluated according to the Banff 2007 classification) during the first year
after transplantation, death censored graft survival (defined as the need for
dialysis or re-transplantation) and patient survival.
Statistical analysis
Statistical analyses were performed using SPSS (version 18.0; SPSS Inc.,
Chicago, IL, USA) and two-sided p-values under 0.05 were considered to
indicate statistical significance. To compare demographics between the
four genotypic groups, the Kruskal–Wallis test was performed for continu-
ous variables and the Chi-square test for categorical variables. The Mann–
Whitney U test was applied to compare continuous variables between two
genotypic groups.
First, univariate analyses were performed on the whole study cohort, for
the association of the four genotypic groups with all transplant outcome
parameters. Subsequently, same analyses were performed for the three
donor types separately (living, DBD, DCD). Kaplan–Meier survival curves
and log-rank testswere performed between the genotypic groups to assess
the difference in death-censored graft survival rates and patient survival. To
assess difference in PNF, DGF and acute rejection between the genotypic
groups, chi-square tests were performed.
Second, multivariable logistic-regression models were constructed to find
independent risk factors for PNF, DGF and acute rejection. Furthermore,
Cox proportional hazards models were used to identify independent risk
factors for death-censored graft failure and patient survival.
Results
No appreciable difference was observed between baseline
characteristics of the study group compared to the original
group (Supporting Information, Table S1). In donors, the
frequency of the C3F allotype was 0.21 and 0.22 in re-
cipients, respectively. These are comparable frequencies
as reported by others and in accordance with the Hardy–
Weinberg equilibrium.
First, the whole study group (all donor types, n = 1265)
was divided into four genotypic groups, as previously de-
scribed. Baseline characteristics between the four geno-
typic groups did not significantly differ (Table 1). Consid-
ering the whole study group, univariate and multivariable
analysis showed that neither the C3 allotype of the donor
nor that of the recipient was associated with PNF, DGF,
acute rejection, death-censored graft survival and patient
survival (Figure 2A, Table 2).
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Figure 2: Death-censored graft survival among the four genotypic groups according to the presence or absence of the donor and
recipient C3F allotype considering all donor types together (A) or only deceased donor types (B). Graft survival was not found to
be significantly different between the four genotypic groups. In recipients of a deceased cardiac dead-donor kidney, superior graft survival
of C3F donor kidneys can be fully attributed to the high incidence of primary nonfunction in recipients of a C3SS donor kidney (C).
As previously indicated, the disparity between the stud-
ies on C3 allotyping and renal allograft outcome might
be explained by an unequal distribution of DBD and DCD
donors among the two study cohorts. Therefore, sim-
ilar analyses were also performed for living, DBD and
DCD donor types separately. For living or DBD donors,
no association was found between C3 donor and recip-
ient allotype on all transplant outcome parameters (data
not shown). Also when analyses were performed for de-
ceased donors (DBD and DCD) separately, no effect of
the donor C3F allotype on transplant outcome was found
(Figure 2B). As the presence of the donor C3F allotype
of kidneys recovered from deceased donors has been
shown to give superior allograft survival rates when trans-
planted into C3SS recipients, we specifically analyzed this
genotypic combination (24). Transplantation of a C3F al-
lelic donor kidney into C3SS recipients was not associated
with superior transplant outcome compared to C3SS into
C3SS recipients for all transplant outcome parameters.
Also, when analyses were performed for C3FF allotypes
664 American Journal of Transplantation 2012; 12: 660–668
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Table 3: Multivariable analyses for transplant outcome of only DCD donors (n = 201) according to the C3 allotype of the donor
SS donor FS/FF donor
Variable (n = 114, reference group) (n = 87) p Value
Posttransplant follow-up time (years)1 6.07 (5.47–6.68) 6.88 (6.33–7.42) 0.0782
Death censored graft survival3 1.00(1) 0.58 (0.30–1.09)(1) 0.079
1.00(2) 0.49 (0.25–0.97)(2) 0.041
Patient survival3 1.00(1) 0.43 (0.17–1.12)(1) 0.084
1.00(2) 0.14 (0.04–0.53)(2) 0.003
Primary nonfunction3 1.00(1) 0.22 (0.06–0.78)(1) 0.019
1.00(2) 0.12 (0.02–0.73)(2) 0.021
Delayed graft function3 1.00(1) 0.82 (0.40–1.70)(1) 0.599
1.00(2) 0.75 (0.31–1.79)(2) 0.512
Acute rejection3 1.00(1) 0.69 (0.36–1.31)(1) 0.255
1.00(2) 0.91 (0.43–1.96)(2) 0.812
Acute rejection classification no. (%)
Overall 33 (29) 19 (22) 0.2534
Borderline 14 (12) 7 (8) 0.3284
Banff IA or IB 11 (10 11 (13) 0.5014
Banff IIA, IIB, or III 8 (7) 1 (1) 0.0434
DCD = deceased cardiac death.
1Mean estimate (95% confidence interval).
2Log-rank test.
3Hazard ratios (95% confidence interval).(1)Crude and (2)adjusted for donor and recipient gender and age, donor type, cold ischemia time,
HLA-A, -B and -DR mismatch, transplant number, recipient primary renal disease, PRA level and the first warm ischemic time.
4Chi-square test.
separately compared to all other allotypes, no differences
were found for all transplant outcome parameters (data not
shown).
However, in the subgroup of only DCD donors (n = 201),
univariate analysis showed that transplantation of C3F al-
lotypic DCD donor kidneys was significantly associated
with lower PNF rates (p = 0.019, Table 3). Baseline char-
acteristics did not significantly differ between the donor
groups according to the presence of the C3F allotype (Ta-
ble 4). Subsequently, multivariable logistic-regression anal-
ysis was performed with covariates that were found to
be significantly associated with PNF by univariate analy-
sis and the factors known from literature influencing graft
outcome. These included donor and recipient gender and
age, donor type, cold ischemia time, HLA-A, -B and -DR
mismatch, transplant number, PRA level and the first warm
ischemic time. Because it was commented that the dispar-
ity in the results between the studies by Brown et al. and
Varagunam et al. might be due to an unequal distribution of
primary kidney disease among the genotypic groups, we
also included primary recipient kidney disease in our mul-
tivariable analysis (25). Multivariable analysis revealed that
the C3F allotype of DCD donor kidneys was independently
associated with a lower incidence of PNF (odds ratio 0.13,
95% CI 0.03–0.67; Table 5). Interestingly, the association
with PNF was strongest among C3SS recipients receiving
a C3SS DCD donor kidney (18%). Moderate or severe vas-
cular rejection (Banff IIA, IIB, III) was the main cause of
PNF in these patients (44%). Also, the incidence of acute
vascular rejection was significantly higher in the first year
after transplantation in recipients of a C3SS compared to
C3F allelic donor kidneys (Table 3).
Death-censored graft survival and patient survival were
also superior in recipients of a C3F allotypic donor kidney,
whereas no associationwas foundwith acute rejection and
DGF (Table 3). The difference in graft survival is likely to be
attributed to the high incidence of PNF in recipients of a
C3SS DCD donor kidney as graft survival rapidly declines
shortly after transplantation (Figure 2c). To investigate this
hypothesis, we analyzed the difference in graft survival,
excluding patients suffering from PNF. In agreement with
what we expected, no significant difference was found in
graft survival between DCD donor kidneys based on the
C3 genotype, excluding patients with PNF (p = 0.864).
However, the difference in patient survival could not be
explained by the high rate of PNF (all patients died with a
functioning transplant).
Discussion
Complement activation has been shown to play an impor-
tant role in the pathogenesis of renal injury after kidney
transplantation. C3 is the central complement component
that is activated by all complement activation pathways
and is, therefore, essential for complement function. Two
polymorphisms, C3S and C3F, of the C3 gene have been
described, resulting in a substitution of glycine (C3F) for
arginine (C3S). Recently, conflicting results regarding the
protective effect of the donor C3F allele on renal allograft
survival of deceased donor kidneys have been published
(23,24). In our study, we confirm a recent report that the
C3F allotype of the donor and recipient is not associated
with renal allograft outcome after kidney transplantation
(23). However, post hoc subgroup analysis within DCD
American Journal of Transplantation 2012; 12: 660–668 665
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Table 4: Donor, recipient and transplant characteristics according to the C3 allotype of only DCD donors (n = 201)
Variable SS donor (n = 114) FS/FF donor (n = 87) p-Value1
Donor characteristics
Age (years)2 46 (35–55) 44 (33–52) 0.233
Sex no. (%)
Male 60 (53) 55 (63) 0.133
Female 54 (47) 32 (37)
Recipient characteristics
Age (years)2 52 (44–61) 52 (42–62) 0.977
Sex no. (%)
Male 57 (66) 73 (64) 0.828
Female 30 (34) 41 (36)
PRA level >5% (%) 7 4 0.802
Previous transplants (% second) 7 10 0.401
Primary kidney disease no. (%)
Glomerulonephritis 21 (18) 16 (18) 0.319
Adult polycystic disease 18 (16) 10 (12)
Renal vascular disease 10 (9) 10 (12)
IgA nephropathy 11 (10) 7 (8)
Pyelonephritis 7 (6) 11 (13)
Diabetes 10 (9) 4 (5)
Chronic 17 (15) 8 (9)
Other 20 (18) 21 (24)
Initial immunosuppression no. (%):
Corticosteroids 107 (94) 81 (93) 0.829
Mycophenolic acid 100 (88) 75 (86) 0.752
Cyclosporin 104 (91) 78 (90) 0.706
Azathioprine 5 (4) 3 (3) 0.737
Tacrolimus 3 (3) 1 (1) 0.457
ATG 5 (4) 3 (3) 0.737
Anti-CD3 moab 1 (1) 1 (1) 0.848
Interleukin-2 RA 43 (38) 24 (28) 0.132
Sirolimus 1 (1) 1 (1) 0.848
Transplant characteristics
First warm ischemia time (min)2 18 (15–23) 19 (15–23) 0.935
Cold ischemia time (h)2 18 (15–21) 17 (14–21) 0.444
HLA no. of 0 mismatches (%) 10 (9) 7 (8) 0.461
DCD = deceased cardiac death; PRA = panel reactive antibody; ATG = antithymocyte globulin; moab = monoclonal antibody; RA =
receptor antagonist.
1All p-values are two-sided. Mann–Whitney test for continuous variables, and chi-square test for categorical variables.
2Median (interquartile range).
donors revealed an independent protective association of
the C3F allotype with PNF.
Earlier studies demonstrated that complement activation
has detrimental effects on allograft function at different
time-points during transplantation. It was demonstrated in
several rodent models that activation of the complement
system is an important mediator of renal IRI (9,26). More-
over, in a mouse allograft model, donor kidneys from C3
deficient animals showed superior graft survival rates com-
pared to wild type donor kidneys (12). In contrast, when
kidneys from wild-type mice were transplanted into C3 de-
ficient mice, no such protection against transplant injury
was found (13). These results indicate that not circulating
C3 in the recipient but local C3 synthesis by the donor kid-
ney is detrimental for renal transplant outcome. Besides,
local renal complement induction and activation can be a
direct result of brain death in the donor which is associ-
ated with impaired renal allograft function in the recipient
(6,7).
Analysis of C3 polymorphisms in both the donor and re-
cipient is an elegant, noninvasive, method to study the
relevance of complement in human kidney transplanta-
tion. Brown et al. were the first to analyze the effect of
the C3 allotype and found superior graft survival rates of
C3F allotypic donor kidneys when transplanted into C3SS
recipients (24). In a separate study by Varagunam et al.,
comprising a much larger transplant cohort, these results
could not be confirmed (23). Unfortunately, it is difficult
to compare both studies since Brown et al. included only
478 kidney transplants, of which, approximately 75%were
derived from deceased donors. Importantly, the protective
effect of the donor C3F allotype was only found in grafts
666 American Journal of Transplantation 2012; 12: 660–668
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Table 5: Multivariable analysis of the risk of primary nonfunction
in recipients of a DCD donor graft
Variable Odds ratio (95% CI) p-Value
C3FS/FF vs. C3SS donor 0.13 (0.03–0.67) 0.014
Donor age 1.05 (1.00–1.11) 0.045
Donor gender 1.30 (0.36–4.74) 0.691
Recipient age 1.03 (0.98–1.09) 0.243
Recipient gender 3.69 (0.73–18.72) 0.122
Second vs. first transplantation 2.41 (0.12–47.16) 0.561
Recipient primary kidney disease 1.15 (0.89–1.48) 0.298
PRA percentage 0.95 (0.70–1.29) 0.757
First warm ischemia time 1.13 (1.02–1.24) 0.016
Cold ischemia time 1.00 (1.00–1.00) 0.004
HLA mismatch 1.70 (1.03–2.82) 0.040
DCD = deceased cardiac death; CI = confidence interval; PRA =
panel reactive antibody. A logistic-regression model was used to
determine the odds ratio for PNF.
recovered fromdeceased donors, not from living donors. In
contrast, the study by Varagunam et al. included solely de-
ceased kidney transplants of 1147 transplantations. More-
over, their study had follow-up data available, 8 years after
transplantation, of 35% compared to 7% in the study by
Brown et al. Hence, the study by Brown et al. is likely to be
underpowered and, therefore, a final study was required
to validate the findings by Varagunam et al.
Our study comprises the largest transplant cohort of 1265
kidney transplantation. Follow-up datawas available 8 years
after transplantation of 30% when all donor-types are con-
sidered and 26% among deceased donor types. Therefore,
results from our cohort are comparable to the study cohort
of Varagunam et al. Among recipients of a living donor kid-
ney, we confirmed the study of Brown et al. that no effect
of the C3F allotype on graft outcome is seen. Considering
deceased donor kidneys, we validated the study by Varagu-
nam et al. that the donor and recipient C3 allotype does not
influence PNF, DGF, acute rejection, death-censored graft
survival and patient survival.
However, when subgroup analyses were performed for
DCD donor types separately, the donor C3F allotype was
independently associated with lower rates of PNF in grafts
derived fromDCDdonors. Also, an association of the donor
C3 allotype with graft survival was found, however, these
results could be fully attributed to the high incidence of
PNF in recipients of a C3SS donor kidney. We are aware
that the association found within DCD donors is prelimi-
nary and needs to be validated in other study cohorts. Our
findings of an association within DCD donors might, how-
ever, explain the disparity in findings between the previ-
ous studies by Brown et al. and Varagunam et al. Although
both studies performed analyses within deceased donors,
no differentiation was made between DBD and DCD donor
kidneys. Taking our findings into account, a significant dif-
ference between the proportion of DBD and DCD donors
in both study cohorts might have influenced their results.
We envision that, particularly in DCD grafts experiencing
PNF, the contribution of the C3F allotype is likely to bemost
significant. It is well-known that DCD kidneys that develop
PNF are allografts that have experienced the worst type of
renal injury. Recently, it has been demonstrated that renal
injury and subsequent necrosis of tubular cells can activate
the complement system (27). Therefore we hypothesize
that, in this particular donor-type, the C3 allotype might be
a risk factor for PNF. Obviously, this should be considered
in the context of other well-known risk factors for PNF such
as prolonged cold and first warm ischemia time, and a high
number of HLA mismatches. This risk profile might help to
reveal high-risk patients who require intensive surveillance
or immunosuppression in the recipient.
In conclusion, this study shows that the C3F allotype of the
donor and recipient is not associated with renal allograft
outcome after kidney transplantation. Subgroup analysis
within DCD donors revealed an independent protective as-
sociation of the C3F allotype with PNF, which is preliminary
and warrants further validation in other study cohorts.
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